Novo Nordisk NVO
What does Novo Nordisk do?
Novo Nordisk is a Danish pharmaceutical group that researches, manufactures and sells medicines worldwide. Its focus is on chronic diseases, mainly diabetes and obesity. The Obesity and Diabetes Care segment comprises insulins, GLP-1-based therapies and products for cardiovascular indications. It also includes injection aids such as smart insulin pens and oral formulations for weight management.
In the Rare Disease segment, the company offers products for rare blood clotting disorders, rare hormonal diseases and hormone replacement therapy. Revenue arises mainly from the sale of prescription medicines to wholesalers, pharmacies and healthcare systems. Competitively, Novo Nordisk is among the leading providers in the diabetes and obesity market, where it competes mainly with large international pharmaceutical companies. Competitive advantages arise from research expertise, manufacturing capacity for peptide therapies, patent protection and established relationships with physicians and payers.
Score profile
Rank vs. Drug Manufacturers - General (15 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Novo Nordisk ranks among the best in the group Drug Manufacturers - General (8.8/10). On growth, the company ranks below average in the group Drug Manufacturers - General (3.8/10). On valuation (higher = cheaper), the stock ranks above average in the group Drug Manufacturers - General (7.2/10). On financial strength, Novo Nordisk ranks in the middle in the group Drug Manufacturers - General (5.4/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 12.0x | 16.4x | better than 70 % |
| Trailing P/E | 10.3x | 32.3x | better than 96 % |
| PEG ratio | 4.5x | 3.3x | better than 25 % |
| EV/EBITDA | 1.5x | 13.4x | better than 97 % |
| Price/sales | 0.5x | 4.4x | better than 97 % |
| Price/book | 5.5x | 6.8x | better than 61 % |
| Revenue growth | 5.6% | 5.6% | better than 50 % |
| Earnings growth | -15.8% | -5.3% | better than 25 % |
| Gross margin | 83.3% | 74.2% | better than 90 % |
| Operating margin | 40.1% | 34.3% | better than 83 % |
| Net margin | 33.9% | 15.7% | better than 97 % |
| Return on equity | 58.4% | 20.0% | better than 83 % |
| Debt/equity | 61.7% | 119.9% | better than 70 % |
| Current ratio | 0.8x | 1.4x | better than 3 % |
| Free cash flow yield | 18.3% | 4.4% | better than 90 % |
| Dividend yield | 4.4% | 2.2% | – |
| Payout ratio | 45.4% | 60.8% | – |
| Beta | 0.37 | 0.37 | – |
Valuation: what is Novo Nordisk worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Novo Nordisk a model range of 55.38 USD to 55.38 USD per share.
12 analysts, average rating “Hold”, average price target 45.77 USD (+12.5%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand for GLP-1-based therapies for diabetes and obesity largely determines revenue and earnings.
- Sufficient production capacity and delivery capability determine how much demand can be converted into actual sales.
- Reimbursement rules of health insurers and healthcare systems influence market access, prescription volumes and achievable prices.
Risks
- Increasing competition from rival weight-loss drugs and generic or copycat products can put pressure on market share and prices.
- Political and regulatory price pressure, particularly in the US market, can weigh on the profitability of the main products.
- Heavy dependence on a few active ingredients increases vulnerability to patent expiries, safety issues or failed trials.
What to look for with Novo Nordisk
The operating margin shows how well the company offsets price pressure, high research spending and capacity expansion through economies of scale in its core products.